Jan 3, 2017
Validation of Immune Cell Modules in Multicellular Transcriptomic Data
G. Pollara, M. J. Murray, J. M. Heather, R. Byng-Maddick, N. Guppy, M. Ellis, C. T. Turner, B. M. Chain, M. Noursadeghi , PloS ONE , DOI: 10.1371/journal.pone.0169271
Numerous gene signatures, or modules have been described to evaluate the immune cell composition in transcriptomes of multicellular tissue samples. However, significant diversity in module gene content for specific cell types is associated with heterogeneity in their performance. In order to rank modules that best reflect their purported association, we...
Jan 2, 2017
Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer
S. Kim, S. Park, M. S. Cho, W. Lim, B.-I. Moon, S. H. Sung , Journal of Cancer , DOI: 10.7150/jca.17437
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme involved in tumor immune escape. Blockade of the IDO1 pathway is an emerging modality of cancer immunotherapy. Triple-negative breast cancer (TNBC) lacks established therapeutic targets and may be a good candidate for this novel immunotherapeutic agent. The purpose of this study was...
Dec 22, 2016
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression
A. v. Mässenhausen, J. Brägelmann, H. Billig, B. Thewes , A. Queisser, W. Vogel, G. Kristiansen, A. Schröck, F. Bootz, P. Brossart, J. Kirfel, S. Perner , International Journal of Molecular Sciences , DOI: 10.3390/ijms18010007
Head and neck squamous cell carcinoma (HNSCC) remains a clinical challenge and identification of novel therapeutic targets is necessary. The receptor tyrosine kinase AXL has been implicated in several tumor entities and a selective AXL small molecule inhibitor (BGB324) is currently being tested in clinical trials for patients suffering from...
Dec 15, 2016
Stroma in pancreatic cancer: Automated quantification and its prognostic significance
R. J. Torphy, R. Naim, B. Midkiff, K. Volmar, E. Collisson, J. J. Yeh , Cancer Research , DOI: 10.1158/1538-7445.PANCA16-B80
Tumor stroma (TS) is a cardinal component of pancreatic ductal adenocarcinoma (PDAC); it comprises 60 to 90% of tumor volume and is an emerging treatment target. There are conflicting reports of the role that TS plays in disease progression and its prognostic significance. The objective of this study was to...
Dec 13, 2016
MATE2 Expression Is Associated with Cancer Cell Response to Metformin
S. Chowdhury, E. Yung, M. Pintilie, H. Muaddi, S. Chaib, M. Yeung, M. Fusciello, J. Sykes, B. Pitcher, A. Hagenkort, T. McKee, R. Vellanki, E. Chen, R. G. Bristow, B. G. Wouters, M. Koritzinsky , PLoS ONE , DOI: 10.1371/journal.pone.0165214
Background: There is great interest in repurposing the commonly prescribed anti-diabetic drug metformin for cancer therapy. Intracellular uptake and retention of metformin is affected by the expression of organic cation transporters (OCT) 1–3 and by multidrug and toxic compound extrusion (MATE) 1–2. Inside cells, metformin inhibits mitochondrial function, which leads...